Robert Sidonio on the Role of aPCC in Patients Receiving Emicizumab Prophylaxis
Robert Sidonio, Professor of Pediatrics at Emory University Hospital, shared a post on LinkedIn:
”It is our great pleasure to share that our publication “Activated Prothrombin Complex Concentrate in Patients Receiving Emicizumab Prophylaxis: From Evidence to Clinical Practice” is now available for free access online as Pre-proof. Thanks to Takeda for organizing this awesome group of hematologists!”
Read the full article here.
In the recently published article ‘Activated Prothrombin Complex Concentrate in Patients Receiving Emicizumab Prophylaxis: From Evidence to Clinical Practice‘ by Robert F. Sidonio Jr. et al., in the RPTH Journal, the role of Activated Prothrombin Complex Concentrate in patients receiving Emicizumab prophyaxis is discussed.
Stay updated on the latest scientific advancements in the filed with Hemostasis Today.
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?
-
May 27, 2026, 17:09Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
-
May 27, 2026, 16:58Catherine Moran: Important Step Forward as 1st WHO Resolution on Stroke Gets Adopted at WHA79
-
May 27, 2026, 16:08Heghine Khachatryan: Thrombosis in Oncology Remains a Major Healthcare Burden
-
May 27, 2026, 16:00Revealing Critical Gaps in Hemophilia Diagnosis and Access to Care in India – WFH
-
May 27, 2026, 16:00Melissa Hollo: Women Deserve Proactive Care, Not Reactive Care
-
May 27, 2026, 15:59Piotr Czempik: First Report of ROTEM Findings in Triple-Positive APS and Hageman Anomaly